Mytolente (Lanreotide Acetate)

Lanreotide acetate binds to somatostatin receptors, mainly SSTR2 and SSTR5, on endocrine cells. This binding blocks the release of growth hormone and other peptide hormones, thereby reducing hormonal hypersecretion and its clinical effects.

The dosage of Mytolente is individualized. A qualified prescriber determines the appropriate amount, frequency, and duration based on the patient’s specific condition, response to therapy, and clinical guidelines.

Safety data for lanreotide acetate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To request Mytolente, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mytolente (lanreotide) and other agents such as octreotide share a similar mechanism of receptor binding, but they differ in dosing frequency, formulation, and pharmacokinetic profiles. Lanreotide often allows for longer dosing intervals, which can be advantageous for patient convenience.

Mytolente should be stored in a refrigerator at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability.

Mytolente is given by subcutaneous injection. A healthcare professional prepares the dose according to the prescribing information and administers it into the fatty tissue, typically in the abdomen or thigh, following aseptic technique.

Serious adverse events include gallstone formation, pancreatitis, severe hyperglycemia, and allergic reactions such as anaphylaxis. Patients should be monitored for abdominal pain, sudden changes in blood glucose, or signs of hypersensitivity, and seek immediate medical attention if they occur.

Mytolente is contraindicated in individuals with known hypersensitivity to lanreotide acetate or any excipients in the formulation. Caution is also advised for patients with uncontrolled diabetes, active gallbladder disease, or severe renal impairment, and the prescriber should evaluate suitability.